{"id":"NCT01610791","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)","officialTitle":"A Single Arm, Open Label Study to Assess the Safety, Tolerability and Efficacy of Tocilizumab in Active Rheumatoid Arthritis Patients With Inadequate Response to the DMARDs (REMISSION Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2012-06-04","resultsPosted":"2014-07-10","lastUpdate":"2014-07-10"},"enrollment":121,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Single Arm","type":"EXPERIMENTAL"}],"summary":"This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra at a dose of 8 mg/kg intravenously every 4 weeks for 24 weeks (6 infusions).","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events","timeFrame":"Baseline, Weeks 4, 8, 12, 16, 20, and 24","effectByArm":[{"arm":"Tocilizumab 8 mg/kg","deltaMin":48.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":8,"countries":["Morocco"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":121},"commonTop":["Elevation of the AST/ALT levels","Hypercholesterolemia","Hypertriglyceridemia","Bilirubin level elevations","Neutropenia"]}}